Empagliflozin protects the heart against ischemia/reperfusion-induced sudden cardiac death

Jan 5,2024

Empagliflozin is a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor used to lower blood sugar in adults with type 2 diabetes. Empagliflozin also exerts cardioprotective effects independent from glucose control. Empagliflozin did not alter baseline cardiac normal conduction activity. However, empagliflozin eliminated myocardial vulnerability to sudden cardiac death (from 69.2% mortality rate in the control group to 0% in the empagliflozin group) and reduced the susceptibility to reperfusion-induced arrhythmias post I/R injury. Empagliflozin increased phosphorylation of cardiac ERK1/2 after reperfusion injury. Furthermore, inhibition of ERK1/2 using U0126 abolished the anti-arrhythmic action of empagliflozin and ERK1/2 phosphorylation.

Empagliflozin

Pretreatment with empagliflozin protects the heart from subsequent severe lethal ventricular arrhythmia induced by myocardial ischemia and reperfusion injury. These protective benefits may occur as a consequence of activation of the ERK1/2-dependent cell-survival signaling pathway in a glucose-independent manner.

A potential anticancer drug

Empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, is a highly effective and well-tolerated antidiabetic drug. In addition to hypoglycemic effects, empagliflozin has many other effects, such as being hypotensive and cardioprotective. It also has anti-inflammatory and antioxidative stress effects in diabetic nephropathy. Several studies have shown that empagliflozin has anticancer effects. SGLT2 is expressed in a variety of cancer cell lines. The SGLT2 inhibitor empagliflozin has significant inhibitory effects on certain types of tumor cells, such as inhibition of proliferation, migration and induction of apoptosis. In conclusion, empagliflozin has promising applications in cancer therapy as a drug for the treatment of diabetes and heart failure.

References:

[1] ZHAOYANG HU. Empagliflozin protects the heart against ischemia/reperfusion-induced sudden cardiac death.[J]. Cardiovascular Diabetology, 2021. DOI:10.1186/s12933-021-01392-6.

[2] WENWEN WU. Empagliflozin: a potential anticancer drug.[J]. Discover. Oncology, 2023. DOI:10.1007/s12672-023-00719-x.

  • Related articles
  • Related Qustion
See also
4

2,5-Furandicarboxylic acid can replace petroleum-based terephthalic acid to produce biobased plastic polyethylene furan dicarboxylate (PEF) due to the similarity in its functional group with terephthalic acid.....

Jan 5,2024Organic Chemistry

The sharing of electrons between O and H is unequal, with the electrons more strongly drawn towards O. This results in an overall polar molecule.....

Jan 5,2024Organic Chemistry

Empagliflozin

864070-44-0

Empagliflozin manufacturers

  • Empagliflozin
  • 864070-44-0 Empagliflozin
  • $220.00 / 1Kg/Bag
  • 2024-11-04
  • CAS:864070-44-0
  • Min. Order: 1Kg/Bag
  • Purity: 99% up, High Density
  • Supply Ability: 20 tons
  • Empagliflozin
  • 864070-44-0 Empagliflozin
  • $39.00 / 5mg
  • 2024-11-04
  • CAS:864070-44-0
  • Min. Order:
  • Purity: 99.89%
  • Supply Ability: 10g
  • Empagliflozin
  • 864070-44-0 Empagliflozin
  • $1.00 / 1kg
  • 2024-11-04
  • CAS:864070-44-0
  • Min. Order: 1kg
  • Purity: 98%
  • Supply Ability: 1 ton